Braveheart Bio is naming Marc Evanchik Chief Scientific Officer (CSO) and appointing Brittany de Temple Senior Vice President ...
Braveheart Bio, a clinical-stage biotechnology company developing next-generation therapeutics for hypertrophic cardiomyopathy (HCM) and related cardiovascular conditions, today announced that Marc ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results